Entonox
ApprovedSmall molecule
Entonox is one of 46 small molecule programs targeting Sedation. It is currently in Approved.
2
Indications
5
Total Trials
2
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
191 competitors in Cognition
#DrugCompanyPhaseTrials
1Evista
Eli LillyPhase 3
Entonox
SSheffield Teaching Hospitals NHS Foundation Trust
Approved
Estrace
Novo NordiskPreclinical
Activella
Eli LillyPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Florinef
Alnylam PharmaceuticalsPreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Veramyst
GSKPreclinical
Galvus
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Women1 trial
The Effect of Entonox on Stages of Labor in Nulliparous Women
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·N/A·NCT04321642·80 enrolled
Sedation1 trial
A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy
Terminated·—·Phase 4·NCT01744184·62 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Entonox. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details